Sartorius has launched a new integrated manufacturing and quality control system for autologous cell therapies, targeting one of the field’s biggest problems: how to make personalized treatments such as CAR-T at scale without driving costs even higher. The new Eveo Cell Therapy Platform combines cell selection, activation, gene modification, expansion, wash and concentration, final formulation, and QC into a closed, modular workflow that can run multiple patient batches in parallel.
The company says the compact platform could sharply increase output in existing facilities. In a pilot with cell therapy CDMO ElevateBio, a single operator was able to process eight patient batches at once in the cleanroom space typically used for two. Based on a seven-day manufacturing cycle and 50 production weeks per year, Sartorius estimates that Eveo could produce more than 350 doses annually in a footprint that currently yields around 100. Financial modeling, the company says, suggests manufacturing costs in CAR-T processes could fall by about 90 percent.
“Cell therapies are redefining medical possibilities. Yet, they remain accessible to only a small share of patients because manufacturing is complex, capacity-constrained and therefore expensive,” said René Fáber, member of the Executive Board at Sartorius. “By combining raw materials, production equipment, software and QC assays into a scalable system, we enable our customers to expand output, significantly reduce cost per dose and shorten vein-to-vein time for patients.”
Sartorius plans to begin taking orders for the Eveo Cell Therapy Platform in September 2026, with first deliveries expected in 2027. ElevateBio, which helped test the system, will receive early access as a preferred partner.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
